DBDouglas R. Bish

Douglas R. Bish

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Douglas R. Bish has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Novel Adaptive Testing Scheme for Multidisease Testing

    by Douglas R. Bish, Ebru K. Bish, Merve Bodur, Berk Görgülü

    Testing Smarter, Not More: An Adaptive Approach In the paper titled “A Novel Adaptive Testing Scheme for Multidisease Testing,” Douglas Bish, Ebru Bish, Merve Bodur, and Berk Görgülü develop an adaptive, cost-efficient testing scheme for lab-based multidisease testing, essential for diagnosis and screening, particularly for disease groups that share symptoms but require disease-specific treatments (e.g., respiratory, gastrointestinal, or sexually transmitted diseases). Their proposed adaptive strategy integrates multiplex assays and pooled testing in a novel way, utilizing modern automated testing technologies to build a customized follow-up test for each person, covering only the diseases flagged in that person’s relevant pooled tests. Optimizing such adaptive designs is mathematically demanding, but in a case study of 18 respiratory diseases, based on data from the Centers for Disease Control and Prevention, their adaptive designs yield substantial cost savings (51%–61%) relative to current practice under forecast error and highly seasonal prevalences. By lowering the cost per subject, adaptive designs can expand testing capacity and support earlier detection under resource constraints.

  • Behaviorally Informed Strategies for Infectious Disease Mitigation: Balancing Incentives and Screening

    by Sait Tunç, Berk Görgülü, Marie J. Rabil, Douglas R. Bish, Ebru K. Bish

    When Screening and Vaccine Incentives Work Better Together When vaccine mandates are not feasible, institutions may rely on vaccination rewards or routine screening of the unvaccinated. The study shows these tools can be more powerful when designed together. Exempting vaccinated individuals turns screening into a nonmonetary incentive while retaining its role in detecting infections. The authors develop a behaviorally informed framework that accounts for vaccine hesitancy, community preferences, limited budgets, and testing capacity. Rather than committing to a rigid plan, the framework learns from surveys and vaccination data and adapts screening as community behavior unfolds. The analysis reveals that incentives and screening are not always substitutes: under some conditions, each strengthens the value of the other. In a realistic college-campus case study using a detailed epidemic model, the adaptive strategy reduced infections and hospitalizations while adhering more closely to budget than incentive-only or screening-only approaches. The findings offer practical guidance for designing flexible mitigation plans for future outbreaks in universities and other close communities.

  • Disease Bundling or Specimen Bundling? Cost- and Capacity-Efficient Strategies for Multidisease Testing with Genetic Assays

    by Douglas R. Bish, Ebru K. Bish, Hussein El Hajj

    Problem definition: Infectious disease screening can be expensive and capacity constrained. We develop cost- and capacity-efficient testing designs for multidisease screening, considering (1) multiplexing (disease bundling), where one assay detects multiple diseases using the same specimen (e.g., nasal swabs, blood), and (2) pooling (specimen bundling), where one assay is used on specimens from multiple subjects bundled in a testing pool. A testing design specifies an assay portfolio (mix of single-disease/multiplex assays) and a testing method (pooling/individual testing per assay). Methodology/results: We develop novel models for the nonlinear, combinatorial multidisease testing design problem: a deterministic model and a distribution-free, robust variation, which both generate Pareto frontiers for cost- and capacity-efficient designs. We characterize structural properties of optimal designs, formulate the deterministic counterpart of the robust model, and conduct a case study of respiratory diseases (including coronavirus disease 2019) with overlapping clinical presentation. Managerial implications: Key drivers of optimal designs include the assay cost function, the tester’s preference toward cost versus capacity efficiency, prevalence/coinfection rates, and for the robust model, prevalence uncertainty. When an optimal design uses multiple assays, it does so in conjunction with pooling, and it uses individual testing for at most one assay. Although prevalence uncertainty can be a design hurdle, especially for emerging or seasonal diseases, the integration of multiplexing and pooling, and the ordered partition property of optimal designs (under certain coinfection structures) serve to make the design more structurally robust to uncertainty. The robust model further increases robustness, and it is also practical as it needs only an uncertainty set around each disease prevalence. Our Pareto designs demonstrate the cost versus capacity trade-off and show that multiplexing-only or pooling-only designs need not be on the Pareto frontier. Our case study illustrates the benefits of optimally integrated designs over current practices and indicates a low price of robustness.Funding: This work was supported by the National Science Foundation [Grant 1761842].Supplemental Material: The online appendix is available at https://doi.org/10.1287/msom.2022.0296 .


  • Novel Pooling Strategies for Genetic Testing, with Application to Newborn Screening

    by Hussein El Hajj, Douglas R. Bish, Ebru K. Bish, Denise M. Kay

    Newborn screening (NBS) is a state-level initiative that detects life-threatening genetic disorders for which early treatment can substantially improve health outcomes. Cystic fibrosis (CF) is among the most prevalent disorders in NBS. CF can be caused by a large number of mutation variants to the CFTR gene. Most states use a multitest CF screening process that includes a genetic test (DNA). However, due to cost concerns, DNA is used only on a small subset of newborns (based on a low-cost biomarker test with low classification accuracy), and only for a small subset of CF-causing variants. To overcome the cost barriers of expanded genetic testing, we explore a novel approach, of multipanel pooled DNA testing. This approach leads not only to a novel optimization problem (variant selection for screening, variant partition into multipanels, and pool size determination for each panel), but also to novel CF NBS processes. We establish key structural properties of optimal multipanel pooled DNA designs; develop a methodology that generates a family of optimal designs at different costs; and characterize the conditions under which a 1-panel versus a multipanel design is optimal. This methodology can assist decision-makers to design a screening process, considering the cost versus accuracy trade-off. Our case study, based on published CF NBS data from the state of New York, indicates that the multipanel and pooling aspects of genetic testing work synergistically, and the proposed NBS processes have the potential to substantially improve both the efficiency and accuracy of current practices. This paper was accepted by Stefan Scholtes, healthcare management. Funding: This work was supported by National Science Foundation [Grant 1761842]. Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation. Supplemental Material: The data files and e-companion are available at https://doi.org/10.1287/mnsc.2021.4289 .


  • Optimal Genetic Screening for Cystic Fibrosis

    by Hussein El Hajj, Douglas R. Bish, Ebru K. Bish

    Improving Newborn Screening for Genetic DiseasesScreening newborns for life-threatening genetic diseases is an important public health initiative. Cystic fibrosis is one of the most prevalent diseases in this context. As part of the cystic fibrosis screening process, all states in the United States use multiple tests, including genetic tests that detect a subset of the more than 300 genetic variants (specific mutations) that cause cystic fibrosis. In “Optimal Genetic Screening for Cystic Fibrosis,” El-Hajj, D.R. Bish, and E.K. Bish develop a decision support model to select which genetic variants to screen for, considering the trade-off between classification accuracy and testing cost, and the technological constraints that limit the number of variants selected. Because variant prevalence rates are highly uncertain, a robust optimization framework is developed. Further, two commonly used cystic fibrosis screening processes are analytically compared, and conditions under which each process dominates are established. A case study based on published data are provided.


  • Screening multi‐dimensional heterogeneous populations for infectious diseases under scarce testing resources, with application to COVID‐19

    by Hussein El Hajj, Douglas R. Bish, Ebru K. Bish, Hrayer Aprahamian

    Testing provides essential information for managing infectious disease outbreaks, such as the COVID‐19 pandemic. When testing resources are scarce, an important managerial decision is who to test. This decision is compounded by the fact that potential testing subjects are heterogeneous in multiple dimensions that are important to consider, including their likelihood of being disease‐positive, and how much potential harm would be averted through testing and the subsequent interventions. To increase testing coverage, pooled testing can be utilized, but this comes at a cost of increased false‐negatives when the test is imperfect. Then, the decision problem is to partition the heterogeneous testing population into three mutually exclusive sets: those to be individually tested, those to be pool tested, and those not to be tested. Additionally, the subjects to be pool tested must be further partitioned into testing pools, potentially containing different numbers of subjects. The objectives include the minimization of harm (through detection and mitigation) or maximization of testing coverage. We develop data‐driven optimization models and algorithms to design pooled testing strategies, and show, via a COVID‐19 contact tracing case study, that the proposed testing strategies can substantially outperform the current practice used for COVID‐19 contact tracing (individually testing those contacts with symptoms). Our results demonstrate the substantial benefits of optimizing the testing design, while considering the multiple dimensions of population heterogeneity and the limited testing capacity.


  • Open Access

    A robust pooled testing approach to expand COVID-19 screening capacity

    by Douglas R. Bish, Ebru K. Bish, Hussein El-Hajj, Hrayer Aprahamian

    Limited testing capacity for COVID-19 has hampered the pandemic response. Pooling is a testing method wherein samples from specimens (e.g., swabs) from multiple subjects are combined into a pool and screened with a single test. If the pool tests positive, then new samples from the collected specimens are individually tested, while if the pool tests negative, the subjects are classified as negative for the disease. Pooling can substantially expand COVID-19 testing capacity and throughput, without requiring additional resources. We develop a mathematical model to determine the best pool size for different risk groups, based on each group’s estimated COVID-19 prevalence. Our approach takes into consideration the sensitivity and specificity of the test, and a dynamic and uncertain prevalence, and provides a robust pool size for each group. For practical relevance, we also develop a companion COVID-19 pooling design tool (through a spread sheet). To demonstrate the potential value of pooling, we study COVID-19 screening using testing data from Iceland for the period, February-28-2020 to June-14-2020, for subjects stratified into high- and low-risk groups. We implement the robust pooling strategy within a sequential framework, which updates pool sizes each week, for each risk group, based on prior week’s testing data. Robust pooling reduces the number of tests, over individual testing, by 88.5% to 90.2%, and 54.2% to 61.9%, respectively, for the low-risk and high-risk groups (based on test sensitivity values in the range [0.71, 0.98] as reported in the literature). This results in much shorter times, on average, to get the test results compared to individual testing (due to the higher testing throughput), and also allows for expanded screening to cover more individuals. Thus, robust pooling can potentially be a valuable strategy for COVID-19 screening.


  • Optimal Group Testing: Structural Properties and Robust Solutions, with Application to Public Health Screening

    by Hrayer Aprahamian, Douglas R. Bish, Ebru K. Bish

    We provide a novel regret-based robust formulation of the Dorfman group size problem considering the realistic setting where the prevalence rate is uncertain, establish key structural properties of...


  • Equity in genetic newborn screening

    by Hussein El Hajj, Douglas R. Bish, Ebru K. Bish

    State‐level newborn screening allows for early treatment of genetic disorders, which can substantially improve health outcomes for newborns. As the cost of genetic testing decreases, it is becoming an essential part of newborn screening. A genetic disorder can be caused by many mutation variants; therefore, an important decision is to determine which variants to search for (ie, thepaneldesign), under a testing budget. The frequency of variants that cause a disorder and the incidence of the disorder vary by racial/ethnic group. Consequently, it is important to consider equity issues in panel design, so as to reduce disparities among different groups. We study the panel design problem using cystic fibrosis (CF) as a model disorder, considering the trade‐offs between equity and accuracy, under a limited budget. Most states use a genetic test in their CF screening protocol, but panel designs vary, and, due to cost, no state's panel includes all CF‐causing variants. We develop models that design equitable genetic testing panels, and compare them with panels that maximize sensitivity in the general population. Our case study, based on realistic CF data, highlights the value of equitable panels and provides important insight for newborn screening practices.